Companies Partner to Provide Digital Security

Digimarc Corp. (Beaverton, OR; DMRC) and AlpVision (Vevey, Switzerland) have formed a worldwide strategic license agreement to drive product security. Digimarc supplies digital watermarking technologies and solutions, and AlpVision offers brand protection and anti-counterfeiting solutions. The agreement enables Digimarc to benefit from AlpVision’s expertise in brand protection security solutions and enhances AlpVision's access to the U.S. market.

“We are pleased to partner with AlpVision in support of their efforts to provide brand protection and anticounterfeiting solutions for customers in pharmaceuticals and other industries,” said Digimarc’s CEO, Bruce Davis, in a press release. “AlpVision is a leader in commercializing invisible digital marking to detect counterfeiting, and has an impressive list of customers and partners across a wide range of industries.  We look forward to working with them in the launch of their U.S. office and marketing initiatives.”

“Digimarc’s patent portfolio features a number of very valuable approaches to support our goal of providing novel, innovative technologies, products, and services to our customers in the United States and around the world,” said Fred Jordan, CEO of AlpVision, in the press release. “We look forward to a long, successful relationship with Digimarc, working together to strengthen our position in the market for anti-counterfeiting applications and services.”

Digimarc offers technologies that create digital identities for all forms of media and many common objects. Embedded digital IDs are imperceptible to humans, but not to computers, networks, and devices. Mobile phones, for instance, can use cameras and microphones as sensory inputs to “see, hear, and understand” the world around them within the context of their environment.

AlpVision S.A develops digital invisible marking technologies for brand protection. In 2001, the company invented authentication technology that has since been used worldwide in the tobacco and pharmaceutical industries.

No votes yet